Hafrun Fridriksdottir - Feb 8, 2022 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role
Executive VP, Global R&D
Signature
/s/ Dov Bergwerk as attorney-in-fact for Hafrun Fridriksdottir
Stock symbol
TEVA
Transactions as of
Feb 8, 2022
Transactions value $
-$55,412
Form type
4
Date filed
2/10/2022, 03:09 PM
Previous filing
Aug 12, 2021
Next filing
Mar 2, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TEVA Ordinary Shares Options Exercise +16.1K +38.93% 57.5K Feb 9, 2022 Direct F1, F2
transaction TEVA Ordinary Shares Sale -$55.4K -6.12K -10.63% $9.06 51.4K Feb 9, 2022 Direct F1, F3, F4, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TEVA Restricted Share Units Options Exercise $0 -16.1K -100% $0.00* 0 Feb 9, 2022 Ordinary Shares 16.1K Direct F2, F6
transaction TEVA Restricted Share Units Award $0 +51.5K $0.00 51.5K Feb 8, 2022 Ordinary Shares 51.5K Direct F2, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3 The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F4 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.06 to $9.075, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
F6 Restricted share units were granted on February 9, 2018, with 16,120 having vested on each of February 9, 2020 and February 9, 2021 and 16,121 having vested on February 9, 2022.
F7 Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 4, 2022.